Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $1.22, $0.42 better than the analyst estimate of $0.80. Revenue for the quarter came in at $63 million versus the consensus estimate of $50.88 million.

Financial Highlights:

• Total revenue for the third quarter of 2017 grew 67% to $63.0 million compared to $37.8 million in the third quarter of 2016;
  • Royalty revenue increased to $43.6 million compared to $26.2 million in Q3 2016;
  • Product sales decreased to $6.9 million compared to $7.8 million in Q3 2016;
• Q3 2017 income before income tax provision was $24.5 million;
• Q3 2017 net income was $15.4 million, or $1.03 per basic and $0.98 per diluted share, compared to a net income of $12.0 million, or $0.77 per basic and $0.73 per diluted share in Q3 2016;
• Q3 2017 Adjusted Non-GAAP net income was $19.2 million, or $1.27 per basic and $1.22 per diluted share, compared to Adjusted Non-GAAP net income of $14.7 million, or $0.95 per basic and $0.89 per diluted share in the prior year quarter. For a full reconciliation of Adjusted Non-GAAP net income to the most comparable GAAP financial measures, please see the tables at the end of this press release; and,
• Cash and cash equivalents were $97.5 million and accounts receivable were $71.6 million as of September 30, 2017.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.